Mass Spectrometry & Spectroscopy
Partnership to Develop Biomarker Discovery Centre and Multi-Omics Centre for Precision Medicine Announced
Mar 31 2016 Read 777 Times
Sciex has announced that The University of Manchester, UK, has invested in a large suite of high-end Sciex mass spectrometers for targeted and next-generation proteomics for its new Stoller Biomarker Discovery Centre. With Sciex’s SWATH® Acquisition technologies, the Centre will be one of the biggest clinical proteomics facilities in the world. It will focus on industrialising proteomics research, and spearhead a series of biomarker development projects and international collaborations.
The Centre, which is supported initially by £18 million in funding, will also provide valuable research and analytical resources for the new Sciex Multi-omics Centre for Precision Medicine, a partnership between Sciex and the Stoller Biomarker Discovery Centre at The University of Manchester. The new centre, expected to open in mid-2016, will include Sciex scientists working in partnership with University researchers to develop and trial new omics workflows in a real-world setting.
The University of Manchester’s new research centre will rely on Sciex’s TripleTOF® 6600 Systems with SWATH Acquisition for highly reproducible and large-scale biomarker discovery and validation. The University of Manchester has also invested in a number of Sciex QTRAP® 6500 Systems that will allow its researchers to quickly convert the novel biomarker discoveries into routine MRM-based targeted proteomics assays, rather than spending many months generating antibody-based immunoassays, which have recently been linked in the media to the reproducibility crisis in scientific research.
“The Sciex TripleTOF instruments are the best suited systems for SWATH Acquisition,” explained Professor Whetton. “We also chose the Sciex QTRAP instruments for targeted protein quantification, which will allow highly powerful verification and validation of the biomarkers that we will discover through our SWATH next-gen proteomics pipeline.”
“We aim to become the leading city for precision medicine. This partnership with Sciex will enable us to be at the cutting edge of both mass spectrometry and biomarker discovery, and help us to take forward our complete precision medicine portfolio,” he added.
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles - Choosing the Optimum Plasma Spectrochemistry Technique for Measuring Elemental Impurities in Pharmaceuticals - Monitoring Airborne Molecular Contamination in Indoo...
View all digital editions
Jun 20 2018 Cologne, Germany
Jun 27 2018 Tokyo, Japan
Jul 08 2018 Baltimore, MD, USA
Jul 29 2018 Chicago, IL, USA
Jul 29 2018 Washington DC, USA